Advances in the CD40-mediated Manipulation Strategies
-
Published:2023-03-30
Issue:1
Volume:20
Page:45-52
-
ISSN:2456-2602
-
Container-title:Biosciences Biotechnology Research Asia
-
language:en
-
Short-container-title:Biosci., Biotech. Res. Asia
Author:
Bandyopadhyay Syamdas1ORCID
Affiliation:
1. Department of Zoology, Burdwan Raj College, Burdwan, India
Abstract
ABSTRACT: Immune homeostasis is crucial in a normal physiological, diseased, or pathogenic state and is mediated by numerous biological molecules. Certain pairs of costimulatory molecules, such as CD40-CD154 play major roles in many different situations. The functions of CD40-CD154 are pivotal for the maintenance of the immune system, cancer prevention, promotion of autoimmune disorders, and fighting against many pathogens. Since the discovery of CD40-CD154, numerous approaches have been taken to dissect this pathway favoring the interest of the host. Ranging from generating small peptides to mutated CD40L to agonistic or antagonistic antibodies have been tested in different models with varying levels of success. This review focuses on the various strategies that have been employed to manipulate CD40-CD154 dyad. Comprehensive knowledge of the understanding of different manipulation strategies of the CD40-CD154 pathway could be important for therapeutic purposes.
Publisher
Oriental Scientific Publishing Company
Subject
Drug Discovery,Agronomy and Crop Science,Biotechnology
Reference25 articles.
1. 1. Yazdany, J., & Davis, J. The role of CD40 ligand in systemic lupus erythematosus. Lupus, 2004, 13(5), 377–380. 2. 2. Luo, W., Weisel, F., & Shlomchik, M. J. B Cell Receptor and CD40 Signaling Are Rewired for Synergistic Induction of the c-Myc Transcription Factor in Germinal Center B Cells. 2018, Immunity, 48(2), 313–326.e5. 3. 3. Vonderheide, R. H. CD40 Agonist Antibodies in Cancer Immunotherapy. Annual review of medicine, 2020, (71) 47–58. 4. 4. Seijkens, T. T. P., van Tiel, C. M., Kusters, P. J. H., Atzler, D., Soehnlein, O., Zarzycka, B., Aarts, S. A. B. M., Lameijer, M., Gijbels, M. J., Beckers, L., den Toom, M., Slütter, B., Kuiper, J., Duchene, J., Aslani, M., Megens, R. T. A., van ‘t Veer, C., Kooij, G., Schrijver, R., Hoeksema, M. A., … Lutgens, E. Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. Journal of the American College of Cardiology, 2018, 71(5), 527–542. 5. 5. Boumpas, D. T., Furie, R., Manzi, S., Illei, G. G., Wallace, D. J., Balow, J. E., Vaishnaw, A., & BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis and rheumatism, 2003, 48(3), 719–727.
|
|